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BACKGROUND AND AIM 
The immune system is a complex integrated network of chemical and cellular mediators that 
developed during evolution to defend the body from any form of chemical, traumatic or infective 
insult to their integrity.  
A proper immune response relies on the innate immunity, that is responsible for a first line 
of defense against aggression and the aspecific recognition of a limited repertoire of antigens, and, 
later, on the adaptative immunity which includes chemical and cellular mediators responsible for a 
more powerful and specific defensive response from any form of antigen. Alterations of any part of 
the immune response results in failure of host defense and, in particular, of immunodeficiency, 
autoimmunity and cancer predisposition.  
Recent evidence highlights that the skin participates in a host defenses either acting as a 
primary boundary for germs, as the principal site of environment–host interactions, or directly in the 
developmental process of the immune system. As a matter of fact, skin and skin annexa 
abnormalities, such as skin dryness, brittleness of hair, nail abnormalities and abnormal dentition, 
can be not infrequently associated with distinct forms of immunodeficiency and may be a warning 
sign of immunodeficiency, since both epidermal and thymic epithelium have ectodermal origin. 
Severe combined immunodeficiency diseases (SCIDs) represent a heterogeneous group of 
rare genetic syndromes responsible for severe dysfunctions of the immune system, which share 
similar clinical manifestations. SCID is the most severe form of inherited primary 
immunodeficiency (PID) and its prevalence is approximately 1:100,000 live births, with a higher 
prevalence in males (1). SCIDs are difficult to recognize clinically because so many different 
infectious scenarios can occur. Without a functional cellular and humoral immune system SCID 
patients are susceptible to recurrent infections such as severe bacterial, viral, or fungal infections 
early in life and often present with interstitial lung disease, chronic diarrhea, and failure to thrive. In 
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addition, some patients develop skin rashes, usually caused by maternal T cells transplacental 
engraftment during fetal life or by a wide autoreaction due to the activation of autologous T cells 
against skin components (2, 3). 
Patients affected with particular forms of PID show an increased susceptibility to cancer. In 
particular, a high cancer susceptibility has been reported for a rare form of PID called Ataxia 
Telangiectasia (A-T) whose clinical hallmark is represented by the cerebellar neurodegeneration 
with the loss of Purkinje cells.  Recently, in a few clinical trial sit has been documented that a short-
term treatment with glucocorticoids (GCs) is able to partially rescue either the A-T neurological 
phenotype and lymphocytes proliferation, even though the mechanism of action has not yet been 
defined (4-7).  
Conventionally, SCIDs have been so far classified, on the basis of the involvement of 
different cell lines in the pathogenesis of the disease and of the subsequent different clinical 
immunological phenotypes related to a specific genetic defect. T cell–deficient but normal B cell 
(T−B+) SCID and both T cell– and B cell–deficient (T−B−) SCID, in the presence or absence of 
NK cells (8). This classification helps in directing molecular studies toward a certain genetic 
alteration, since it is representative of the stage where the blockage occurs during the differentiation 
process. 
More recently, advances in next generation DNA sequencing allowed new gene 
identification through whole exome or whole genome sequencing (WES, WGS) of several forms of 
PIDs of unknown causes making the genetic identification of immunodeficiency syndromes more 
efficient (9). Only in the last two years, using this technology 34 new gene defects have been 
identified. Most of these immunodeficiencies are rare, even though some of them occur more 
frequently than what previously reported, as documented by several groups (10). Based on the 
principle of massively parallel sequencing, NGS technology provides an advanced tool to 
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dramatically increase the speed at which DNA can be sequenced at a lower cost as compared to the 
traditional Sanger sequencing approach. 
In this context my PhD program has been focused on the study of some immunological 
disorders, in order to identify new scenarios in pathogenesis, diagnosis and therapeutic approaches. 
This thesis reports the results obtained during my PhD course in “Clinical and Experimental 
Medicine” (XXXI Cycle, years 2015-2018). During these years my research has been focused on 
the study of the following lines of research: 
• positive effect of oral betamethasone administration on the in vitro lymphocytes 
functionality in patients affected with Ataxia-Telangiectasia, and the identification of the 
molecular checkpoint responsible for the partial functional rescue in lymphocytes of the 
patients affected with this disease. 
• characterization of a novel immunodeficiency whose hallmarks are represented by 
high IgM levels, impaired B-cell homeostasis and cancer susceptibility, 
• autoimmune manifestations and the pathogenetic mechanism underlying autoimmunity in a 
specific PID. 
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“In Ataxia-Telangiectasia, the functionality of the IL-7/IL-7Rα axis parallels the 
neurological behavior during in vivo Betamethasone treatment” 
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Introduction 
Ataxia Telangiectasia (A-T) (http://omim.org/entry/208900) is a rare genetic disorder of 
childhood due to mutations in the Ataxia Telangiectasia Mutated (ATM) gene. To date, over 600 
distinct ATM mutations have been reported (www.hgmd.cf.ac.uk/ac/gene.php.gene=ATM). 
Different types of ATM gene mutations are associated to different forms of the disease. Truncating 
mutations cause the classic form of A-T associated to the complete absence of the protein function.  
Splice site mutations or missense mutations with expression of the protein at some extent, thus 
exerting residual kinase activity, are responsible for milder forms of A-T (11).   
ATM exerts a central role in the signal-transduction pathway activated by DNA double strand 
breaks (DSBs), and, therefore, A-T is considered the prototype of the DNA-repair defect 
syndromes. In response to DSB formation, cell cycle arrest and DNA repair occur by the activation 
of nuclear form of ATM and several DNA-repair and cell cycle checkpoint proteins (12). Defects in 
DSBs repair could also account for the high incidence of chromosomal rearrangements involving 
the sites of the immune system genes.  Of note, gene rearrangements and DSBs repair by ATM are 
required for a proper immune cell maturation. ATM deficiency may affect VDJ recombination but 
poorly lymphocyte development. In B cells, the absence of a functional ATM leads to a defect in 
class switch recombination (CSR), thus supporting a role of ATM in this process (13). 
There is also evidence in favor of an extranuclear role for ATM, not involving the DNA damage 
repair process (14). In ATM-deficient cells, the absence of cytosolic functional ATM leads to a 
reduced internalization of phytohaemagglutinin (PHA), depolarization in response to extracellular 
K+, defective Ca2+ mobilization, a decrease in the duration of Ca2+ and Na+ firing and defective 
signaling (15). In the cytoplasm, ATM exists as a soluble protein or inside subcellular organelles, 
such as peroxisomes, important for β-oxidation of fatty acids and detoxification, and endosomes, 
involved in endocytosis and intracellular routing of receptors and other molecules.  Possible targets 
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of cytosolic ATM are the 4EBP1 protein (15), and other molecules involved in oxidative 
metabolism or in cell protection from the metabolic stress (14). 
The clinical phenotype consists of oculocutaneous teleangiectasia, immunodeficiency, high 
incidence of neoplasms and hypersensitivity to ionizing radiations. The hallmarks of the disease are 
related to the progressive neurological degeneration, with a selective depletion of Purkinje cells, 
which greatly impairs the quality of life, invariably confining the patients to wheelchair (16, 17). 
Together with the neurological degeneration, A-T patients show immunodeficiency, usually 
affecting both humoral and cellular responses, even though severe infections are not frequent in 
these patients.  Infections in these patients mainly involve the respiratory tract and seem to be 
related to the neurological alterations themselves rather than to the immune defect (18). The 
prognosis for survival is poor.  
To date, A-T remains an incurable disease that leads relentlessly to death around the third 
decade of life predominantly for progressive neurodegeneration, pulmonary failure with or without 
identifiable pneumonia, and cancer  (12, 19).  
A short-term treatment with glucocorticoids is able to transiently rescue the A-T 
neurological phenotype and to increase lymphocytes proliferation, even though the mechanism of 
action has not yet been fully defined (5, 6, 7). However, these effects have been observed only in a 
few patients, the neurological improvement being inversely correlated with the extent of cerebellar 
atrophy and positively correlated with the antioxidative capacity (7). It should be noticed that the 
variability was not explained by the amount of ATM protein, which was absent in both the 
responders and non-responders. The effect on cell proliferation represents a paradox, since it is in 
contrast with the well-known immunosuppressive role of glucocorticoids. 
IL-7/IL-7R signaling pathway represents a central checkpoint in the cell cycle progression of 
lymphocytes. IL-7R expression is dynamically controlled in T- and B-cell development and is 
highly expressed on naive and memory CD4+ and CD8+ T cells (20, 21). When naive T cells 
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receive Ag stimuli, IL-7Rα is down-regulated and the cells become effector T cells (22). The IL-
7R-chain (IL-7R, CD127) is a prominent gene target of glucocorticoids in that it is up-regulated in 
response to glucocorticoids (23), while it is rapidly down-regulated in response to a number of 
stimuli, including IL-7 (24). A decreased IL-7R expression on activated effector T cells ensures that 
they are short lived and prone to apoptosis, while high expression of IL-7R on naive and memory T 
cells ensures their survival over the long term (25, 26). 
IL-7R, as other signal-transducing cell-surface receptors, are constitutively recycled at the 
cell membrane and, following their binding to the ligand, are internalized through an endocytosis 
mechanism (27). Thereafter, these proteins are sorted in early endosomes and are either returned to 
the cell surface or degraded by proteasomes and/or lysosomes (28). 
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Aims 
This study was aimed to verify whether the positive influence of in-vivo administered low doses of 
GC on the lymphocyte proliferative response correlated with the neurological positive response and 
whether the IL-7/IL-7R axis signaling pathway is implicated in the process. 
 
Materials and methods  
Patients 
Eleven A-T patients were initially studied for the proliferative response to PHA or IL-7. Four of 
these 11 patients, referred at a single Center, were enrolled in a multicenter clinical trial, aimed at 
defining the minimal effective dosage of oral Betamethasone at the dosage of 0.001, 0.005 or 0.01 
mg/kg/day (29). Neurological assessment was performed through the Scale for the Assessment and 
Rating of Ataxia (SARA) at each time-point. In the already published study, all patients were 
categorized as responders, partial responders and non-responders. In this study, patients of a single 
center were further studied at immunological level. PBMCs were collected at specific time points 
during the treatment period.  
 
Cell Culture  
PBMCs were obtained from 11 A-T patients and healthy donors by Ficoll-Hypaque (Biochrom, 
Berlin, Germany) density gradient centrifugation. PBMCs were grown in RPMI-1640 (Lonza, 
Verviers, Belgium) supplemented with 10% fetal bovine serum (FBS; Gibco, Carlsbad, California), 
2 mmol L-glutamine (Gibco, Carlsbad, California), 50 µg/ml gentamycin (Gibco, Carlsbad, 
California), 10% Penicillin-Streptomycin (Lonza, Verviers, Belgium), and cultured at 37°C, 5% 
CO2. PBMCs were put in culture (2 * 105 / well) in triplicate in 96-well plates in RPMI 1640 
containing 10% FBS, 2mM/L L-glutamine and 50 µg/ml gentamycin, with or without PHA (8 
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μg/ml) and IL7 (20 ng/ml), for 72 hours. All the experiments were approved by the Ethical 
Committee for Biomedical Activities of Federico II University, trial registration n. 55/14; Eudract n. 
2014-000454-10. 
 
Flow cytometry 
PBMCs were collected according to informed consent procedure. Lymphocytes were gated on a 
(CD45) forward scatter vs. side scatter dot plot. CD127+, CD25+, CD69+ and HLA-DR+ cells 
were gated from the CD3+ lymphocyte population. Cells were acquired by a flow cytometer FACS-
Canto II (Becton Dickinson, San Jose, CA, USA), equipped with three lasers and eight 
photomultipliers and analyzed with the BD FACSDiva software. 
 
Real-time quantitative reverse transcriptase PCR analysis 
Total RNA from A-T was extracted using TRIzol reagent (Invitrogen, Carlsbad, CA), and phase-
lock gel columns (Eppendorf, Germany) according to the manufacturer’s instructions. RNA was 
reverse transcribed by Transcriptor First Strand cDNA Synthesis Kit (Roche, Germany). The qPCR 
reactions were performed in duplicate. The amplification of the cDNAs was performed using the 
SYBR Green and analyzed with the Light Cycler480 (Roche Applied Systems, Germany). Cycling 
conditions comprised an initial denaturation at 94°C for 5 min, a phase of annealing/extension 
specific for each gene. A dissociation procedure was performed to generate a melting curve for 
confirmation of amplification specificity. Primers used are listed in the Table 1. Results are 
expressed as mean + standard error (SE) and each gene expression was normalized to β-actin as 
housekeeping gene. The relative transcript abundance was represented as -DCt = (Ct gene - Ct 
reference) and the relative changes in gene expression was analyzed using the 2-DDCt method (30).  
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Western blotting 
Total lysates were obtained from PBMCs of A-T patients at all time points during the clinical trial. 
The cells were washed with ice-cold PBS (Lonza, Walkersville, MD) and lysed in lysis solution 
containing 20 mM Tris (pH 8), 137 mM NaCl, 1% Nonidet P-40, 10 mM EDTA, 1 mM 
phenylmethylsulfonylfluoride (PMSF), 1 mM sodium orthovanadatum (Na3VO4), 5 μg/ml 
leupeptin and 5 μg/ml aprotinin on ice for 45 min. Protein concentration was determined by Bio-
Rad Protein Assay, based on Bradford’s method. Proteins were separated on 4-12% 
NovexNuPAGE SDS-PAGE gels (Invitrogen, Carlsbad, CA. Proteins were transferred onto 
nitrocellulose membranes (Sigma-Aldrich, St. Louis, MO). The membranes were then washed three 
times in wash buffer, blocked and incubated with the specific primary antibodies for IL-7Rα (R&D 
System, MN, USA) or Actin (Sigma-Aldrich, St. Louis, MO). Immune complexes were detected 
using the appropriate anti-mouse peroxidase-linked antibodies. ECL reagent (Bio-Rad, 
Woodinville, WA, USA) was used as detection system for visualization.  
 
Confocal microscopy 
PBMCs obtained from A-T patients were washed with PBS (Lonza, Walkersville, MD) and spotted 
on sterile coverslips through Shandon CytoSpin III Cytocentrifuge. Each spot was delimited with 
the DakoPen (Dako, Denmark). Each section was blocked with normal goat serum before staining 
and then treated with a mix of 1:25 IL-7Rα (R&D System, Minneapolis, USA) and 1:300 EEA1 
(Santa Cruz Biotechnology, TX, USA) or Rab-7 (Santa Cruz Biotechnology, TX, USA) rabbit 
antibodies. Appropriate anti-mouse or anti-rabbit peroxidase-linked secondary antibodies were 
used. Nuclear counterstain was performed with 0.05 mg/ml DAPI (4',6-diamidino-2-phenylindole) 
(Vector Laboratories, CA, USA). Images were acquired by a confocal microscope (LSM 510, Zeiss, 
Germany). 
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Statistics 
GraphPad Prism software was used for data analysis. The Student's t-test was used to analyze the 
statistical significance of differences. The minimum acceptable level of significance was p ≤ 0.05 
calculated through two-tailed unpaired Student's t-test. 
 
 
 
RESULTS 
 
Evaluation of the proliferative response in lymphocytes from patients affected with A-T  
Immune deficiency in A-T patients is characterized by poor lymphoproliferative ability. In 
our cohort of A-T patients before the GC therapy (n = 11), the proliferative response to the mitogen 
PHA was reduced by 69% as compared to healthy controls (cpm mean value ± SD: 8061 ± 2549 vs 
25907 ± 8192) (Figure 1A). Similarly, the proliferation following Il-7 stimulation was lower in A-T 
patients than in controls (n = 13) (Figure 1B). The proliferative index (PI) in patients and controls 
was 1.14 ± 0.18 (mean ± SD) and 2.70 ± 0.56, respectively (p = 0.028). We next evaluated whether 
the reduced proliferation to IL-7 correlated to the percentage of circulating CD3+ cells expressing 
IL-7Rα (also known as CD127). In A-T patients, 47.7% of CD3+ gated cells expressed CD127, 
while in the controls they were 82.2% (p = 0.017) (Figure 1C). Moreover, the mean fluorescence 
intensity of CD127+ cells was comparable in both groups (mean ± SD: 1.7 ± 0.09 vs 1.7 ± 0.06) 
(Figure 1D). 
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The immune deficiency is variable among A-T individuals (Chopra et al., CEI 2014) and we 
confirmed that, although the poor lymphoproliferative ability was constant in the same subject over 
the time (data not shown), it was highly variable among different patients. Since a similar 
variability was also observed in the neurological response to oral betamethasone administration, we 
wondered whether there was a correlation between the behavior of lymphoproliferative ability and 
the neurological response to the drug. Thus, by taking advantage of a multicentric clinical trial 
aimed at defining the minimal effective dosage of oral steroid {Cirillo, 2018 #3819}, we compared 
in the 4 A-T patients, referred at a single Center, the immunological and neurological behavior 
during the betamethasone trial. The evaluation of the proliferative response to PHA showed a 19- 
and 15-fold increase only in 2 of the 4 A-T patients (Figure 2A).  Similarly, the proliferative 
response to IL-7 showed a 3- to 4-fold increase in the same patients, at the different time points, and 
again no increase was noted in the other patients (Figure 2B). A correlation between the 
proliferative response to IL-7 and the percentage of CD3+CD127+ cells was found (Figure 2C). Of 
note, as shown in the Figure 2D, a significant inverse relationship between the proliferative 
response to IL-7 and the behavior of the SARA score was found.  
 
 
 
 
 
 
 
 
 
 
17 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
18 
 
 
Since the expression of IL-7Rα varied among A-T patients, we evaluated through Real-Time 
PCR the expression levels of IL-7Rα mRNA in the most responder and the non-responder at all to 
GC. At the transcription level, no difference was found in the IL-7Rα mRNA, expressed as 
percentage of the GILZ steroid target, between the patients (Figure 3A). Similarly, as shown in the 
Figure 3B the amount of the protein in the cytoplasm was comparable between the patients, thus 
supporting what observed at the transcription level.  
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We next analyzed through confocal microscopy the subcellular localization of the molecule 
in the most responder and the non-responder at all to GC. We found that IL-7Rα was expressed in 
responder and non-responder patients in a similar fashion (Figure 4A,B). However, in the 
responders most of the molecule (40%) was localized into the early endosome (EEA1) vesicles, 
differently from the non-responders, in whom the co-localization events on a single cell basis was 
only 7% (Figure 4C). We next evaluated the amount of IL-7Rα internalized and recycled back to 
the cell surface through the late endosomes (Rab-7). We found that IL-7Rα co-localized in the 
recycling endosomes in the responder more that in the non-responder (57 vs 31% of positive cells), 
suggesting that in the non-responders the recycling process of internalized receptor didn’t occur 
properly (Figure 4D). 
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Activation markers 
We next compared through cytometry the up-regulation of the activation markers, such as 
HLA-DR, CD25 and CD69 between the most responder and non-responder at all. As shown in 
Figure 5A, in both patients a high percentage of constitutively activated T cells (CD3+HLADR+) 
was observed. Moreover, in the non-responder at resting condition, the percentage of CD25+ T cells 
was higher (22%) than in the responder (1%). After stimulation with PHA, the CD3+CD25+ and 
CD3+CD69+ cells significantly increased only in the responder (Figure 5A). The increase of the 
activation markers inversely paralleled the behavior of the expression of CD127, which decreased 
upon stimulation only in the responder from 85 to 65 % similarly to the control, suggesting a 
physiological internalization of a functional receptor (Figure 5B). 
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DISCUSSION 
 
In the last few years several studies have documented a positive effect of in-vivo administration of 
steroids on neurological signs of patients affected with A-T. However, this effect was remarkable 
only in a few patients, while other subjects didn’t show any positive response. This variability was 
only partially explained by the extent of the cerebellar atrophy and redox status and was not 
correlated to the amount of the residual ATM protein, in that it was absent in all the patients 
studied. Intriguingly, a similar variability, among the patients receiving the steroid, was also 
observed in the behavior of the PBMC proliferative response to mitogens during the trial. Thus, by 
taking advantage of this clinical and immunological variability, in this study we compared several 
immunological functions, including PBMC proliferative responses, cell activation events and IL-
7/IL-7Rα axis functionality, with the neurological behavior during an in-vivo steroid treatment 
between the most responder patient to GC and the non-responder at all.     
In this study, we documented a significant reduction before the GC treatment of the 
proliferative response to PHA and IL-7 in A-T lymphocytes, as expected. IL-7 is a key 
immunoregulatory cytokine, which plays an essential role in the development and differentiation of 
T cells (31). The biological effects of IL-7 are mediated via IL-7 receptor complex, and has been 
shown that IL-7 promotes a negative feedback on its own receptor by downregulating the 
expression of the IL-7Rα (32), through both suppression of IL-7Rα gene transcription and by 
internalization of existing IL-7Rα protein from the cell membrane (33). The pivotal role of IL-7/IL-
7Rα axis is also underlined by the fact that a partial deficiency in this receptor in humans is 
sufficient to abrogate T-cell development and causes severe combined immunodeficiency (SCID) 
(34). Intriguingly, we found a significant increase of the proliferative response to PHA or IL-7 of 
PBMC only in the patients who responded to GC the most at the neurological evaluation, thus 
indicating a tight correlation between the proliferative responses and the neurological behavior 
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during the in-vivo GC administration. As expected, the proliferative response to IL-7 significantly 
correlated to the percentage of CD3+ cells expressing the IL-7Rα.  
A proper functionality of the IL-7/IL-7Rα axis is based on a continuous turn-over of the 
receptor through its internalization and recycling. The number of cell surface receptor molecules 
represents a continuous equilibrium between the rate of synthesis, internalization and recycling of 
the molecule. The overall process represents a sign of a fully functional receptor turn-over. Upon 
activation, the decrease of the number of surface receptors on the cell membrane directly reflects 
their degradation (35).  
GCs have pleiotropic effects on the growth, differentiation, and function of lymphocytes 
(36). Moreover, they may influence either positively or negatively the function of T cells (37). In 
addition, it has also been reported that IL-7Rα is one of the most prominent gene induced by 
glucocorticoids and that GCs are able to increase its expression in human peripheral T cells. In this 
study, we couldn’t find any difference between the responder and the non-responder in the IL-7Rα 
mRNA expression, as compared to the well-known GC gene target, GILZ. This finding was also 
confirmed at the protein level, in that no difference was observed in the amount of the protein 
between the responder and the non-responder. Taken together these data would suggest an alteration 
of the post-transcriptional events in the IL-7Rα biology. 
Increasing evidence indicates that endocytosis is a necessary step for efficient receptor 
mediated signal transduction (37). The presentation of cytokine receptors at the membrane surface, 
as of other proteins, uses different endocytic pathways, which include clathrin-dependent or 
independent mechanisms (38). Clathrin-mediated endocytosis requires the assembly of a clathrin 
coat on the cytoplasmic side of the membrane, becoming free clathrin-coated vesicles. Clathrin-
dependent endocytosis delivers internalized cell surface components to early endosomes. Here, 
molecules that need to be reutilized are recycled back to the surface or are transported to late 
endosomes for their degradation (39). IL-7Rα is internalized under steady-state and upon IL-7 
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stimulation through clathrin-mediated endocytosis (40). Additional data demonstrate that the use of 
inhibitors of clathrin-dependent endocytosis, as nystatin, induce a reduction of the uptake of the 
receptors in the cells (41). Once internalized, a significant fraction of the receptor is recycled back 
to the cell surface, which is essential to maintain a proper IL-7Rα surface expression.  In this study, 
we found that in the responders, IL-7Rα is internalized by the cell and abundantly sorted into the 
early endosome (EEA1 vesicles), differently from the non-responders who had a higher membrane 
expression of IL-7Rα, and whose vesicles scarcely contained IL-7Rα. Moreover, in the responders a 
higher amount of IL-7Rα, as compared to the non-responder, is destined for the late endosome 
(Rab-7 vesicles), indicating a proper recycling of the receptor. Under experimental conditions, in 
Rab-knockdown cells the lack of Rab is responsible for the accumulation of endocytosed receptors 
on the membrane surface (42), this feature being very similar to what observed in the cell from the 
non-responder patients. Taken together, these data would suggest that in the non-responders the 
overall internalization/recycling process represents a limiting step in cell functionality.  
The abnormalities in the IL-7Rα intracellular trafficking reflects a more general deficiency 
in cell activation, in that the evaluation of the T-cell activation markers, CD69, CD25 and HLA DR, 
revealed that only in the cells from a responder the activation stimuli up-regulated these molecules, 
while their up-regulation in a non-responder was negligible. Moreover, under resting conditions 
cells from the non-responder expressed high levels of CD25 and HLA DR molecules, indicating a 
constitutive activation of T cells. The observation of a poor proliferation to IL-7 associated with 
high basal IL-7Rα expression in the non-responder would indicate a reduced sensitivity to the IL-7, 
presumably, indicating that a normal internalization and turn-over of the molecule is required for a 
proper receptor functionality.  
Recent evidence indicates that ATM is also localized in the cytoplasm, where it is involved 
in exocytosis, intracellular vesicle and/or protein transport and in the autophagy pathway, whose 
alterations have been documented also in other neurodegenerative disorders (Alzheimer’s, 
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Parkinson’s, Huntington’s diseases). During autophagy, the autophagosomes, containing the waste, 
fuse with the lysosomes resulting in the formation of autolysosomes, where the digestion occurs. 
Recently, we documented that, in the absence of ATM, an accumulation of waste material within 
the cytoplasm occurs, indicating that the cell clearance apparatus, involving autophagy and the 
intracellular vesicle trafficking, is abnormal in A-T (43). Therefore, it is conceivable to hypothesize 
that the abnormal IL-7Rα trafficking is a more general phenomenon related to the abnormalities of 
the cell clearance process. 
The tight correlation between the immunological improvement during in-vivo GC 
administration and the neurological response to the therapy would suggest that cell biology studies 
on peripheral lymphocytes are a precious tool to investigate the overall disease pathogenesis and to 
pave the way to explore innovative therapeutic interventions, able to interfere in the cell biology 
and eventually in modulating the expressivity of the disease phenotype. Since in all patients studied 
ATM was undetectable, the clear-cut variability in the neurological and immunological responses 
would imply that additional genetic or environmental factors are capable to modulate the 
phenotypic expression of the disease. 
 
 
The data herein reported have been submitted as Original article on Journal of Clinical and 
Experimental Immunology 
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CHAPTER II 
 
 
 
 
“Characterization of Patients With Increased IgM Levels, B-Cell Differentiation 
Blockage, Lymphoproliferation and DNA Repair Defect” 
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The earliest evidence that individuals with PIDs develop cancer was reported in 1963 (44). An 
increasing number of reports subsequently indicated that subjects with congenital abnormalities of 
the immune system are at a high risk for developing cancer including lymphoma and stomach, 
breast, bladder, and cervical epithelial cancers (45) 
 The overall risk for children with PIDs of developing malignancy is estimated at 4–25% (44, 
46). The type of malignancy that is seen is highly dependent on the precise PID, the age of the 
patient, and probably viral infection indicating that different pathogenic mechanisms may be 
implicated in each case (46). According to the Immunodeficiency Cancer Registry (ICR) database 
NHL and Hodgkin’s disease (HD) account for 48.6 and 10%, respectively, of the malignancies seen 
in patients with PIDs. Genomic instability due to defective DNA repair processes and other 
unknown mechanisms in PID patients leads to an enhanced risk of cancer.  
 The findings of elevated serum IgM with low IgG, IgA, or IgE in the setting of immune 
deficiency leads most immunologists toward a diagnosis of Hyper IgM syndrome (HIGM), rare 
inherited PIDs characterized by class switch recombination defects (CSR) and sometimes impaired 
somatic hypermutation (SHM). SHM plays a role in the selection and proliferation of B cells 
expressing a B-cell receptor (BCR) with a high affinity for the antigen and does require the integrity 
of the cell DNA repair machinery. 
The majority of these forms are caused by X-linked (XL) or autosomal recessive (AR) 
defects in the CD40 ligand/CD40 signaling pathway or AR disorders involving activation-induced 
cytidine deaminase (AID), or in the uracil DNA glycosylase (UNG). Other HIGM are caused by 
mutations or in the X-linked nuclear factor k-B essential modulator (NEMO) gene, reported in 
patients affected with ectodermal dysplasia. In all these cases, both SHM and CSR processes are 
equally impaired. The unique condition, so far described, of dissociation between the CSR and 
SHM process is represented by the autosomal dominant mutation in C terminal end of AID in 
patients showing defective CSR but intact SHM. This observation would imply a different 
molecular control of the 2 processes. To date, in spite of the identification of new genetic defects 
associated with HIGM through NGS technologies, in about the 15% of the cases of HIGM patients, 
the molecular defect still remains to be defined. 
The clinical phenotype of HIGM is invariably severe and characterized by increased 
susceptibility to recurrent bacterial and opportunistic infections, neutropenia, autoimmunity and 
cancer susceptibility.  
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The presence of elevated levels of IgM were also reported associated with other 
immunological defects like RAG2, ATM and ARTEMIS deficiency or to acquired causes,  such as 
in autoimmune diseases, with IgM autoantibodies, or in chronic infections. In B-cell 
lymphoproliferative disorders, elevated monoclonal IgM levels may also be found. 
 
In this paper, submitted on Journal of Clinical Immunology, we report on a group of 
unrelated patients with very high polyclonal IgM levels, resembling a HIGM of unknown molecular 
defect, whose clinical course was complicated by the occurrence of a lymphoproliferative disorder. 
In these patients an evaluation of B-cell subsets has also been performed, revealing a reduction of 
memory and switched memory B cells. Through the comet alkaline and micronucleus (MN) assays 
on peripheral blood lymphocyte or fibroblast cultures an increased genotoxicity was documented. In 
order to evaluated a molecular cause of the disorder NGS analysis was performed, revealing in two 
subjects mutations in PIK3R1 or ITPKB genes, implicated in B- and T-cell development. 
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CHAPTER III 
 
 
 
 
“New insights in the pathogenesis of Ataxia-Telangiectasia disorders” 
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Ataxia-Telangiectasia clinical hallmark is represented by the cerebellar neurodegeneration with 
the loss of Purkinje cells (20).  Recently, in a few clinical trials it has been documented that a short-
term treatment with glucocorticoids (GCs) is able to partially rescue the A-T neurological 
phenotype and lymphocytes proliferation even though the mechanism of action has not yet been 
defined (4-7).  
Evidence exists that ATM exerts additional functions in the cytoplasm independent of its 
role in the DNA damage response (21), such as participation to the autophagy pathway (22). To 
date, many studies have been performed to identify the pathogenic mechanism responsible for the 
disease, mainly focusing on the nuclear activity of ATM protein. Thus, the pleiotropic aspects of the 
phenotype have only partially been clarified.  
Autophagy alterations have been implicated in several chronic nervous system disorders, 
such as proteinopathies (Alzheimer’s, Parkinson’s, Huntington’s diseases) and acute brain injuries 
(23), whose hallmarks are organelle damage, synaptic dysfunction and neuronal degeneration. 
Autophagy, known originally as an adaptive response to nutrient deprivation in mitotic cells, 
including lymphocytes, is now recognized as an arbiter of neuronal survival and homeostasis in that 
neurons are post-mitotic cells, which require effective protein degradation to prevent accumulation 
of toxic aggregates. Reactive oxygen species (ROS) generation from dysfunctional mitochondria, as 
documented in cells from A-T patients, is a potent trigger of autophagy, which acts to clean up 
damaged organelles (24). It has been demonstrated that in the presence of elevated ROS levels, the 
activation of the serin/threonine kinase ATM in the cytoplasm leads to activation of LKB1 tumor 
suppressor gene, which, in turn, phosphorylates and activates AMP protein kinase (AMPK) (25). 
AMPK regulates several metabolic processes and activates Tuberous sclerosis complex 2 (TSC2), 
which participates in energy sensing and growth factor signaling (26). TSC2, by inhibiting the 
GTPase Rheb, is able to repress mTOR kinase, a key regulator of the protein synthesis and cell 
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growth, thus leading to the activation of autophagy (27). The repression of mTOR complex 1 
(mTORC1) signaling results in the absence of phosphorylation of p70 ribosome S6 kinase 
(p70S6K) and eukaryotic initiation factor 4E-binding protein 1 (4EBP1), direct targets of the mTOR 
kinase, involved in protein synthesis and survival. 
Thus, a direct effect of ATM-mediated inhibition of mTORC1 is the activation of 
autophagy, a dynamic process, which includes the initiation, formation, maturation and degradation 
of autophagosomes (APs). The lipidation of LC3 molecule, through the conjugation of 
phosphatidylethanolamine (PE) converting the cytosolic LC3 (LC3-I) to the autophagic vesicle-
associated form (LC3-II), is essential for autophagy induction, and thus for APs visualization by 
transmission electronic microscopy (TEM). The lipidated LC3-II form may also be visualized under 
fluorescence microscope in that it shows a punctate staining pattern and by western blot in that it 
has faster electrophoretic mobility compared with diffused LC3-I form (28). An increase of LC3-II 
form may result from either an enhancement of APs biogenesis or inhibition of APs degradation, or 
may be due by other mechanisms (28). p62/sequestosome (SQSTM1), is a further biomarker widely 
used to evaluate the appropriateness of autophagic activity. It can bind LC3 protein to promote the 
recruitment of unwanted material into autophagosomes and the subsequent degradation through 
autolysosomes. When a normal autophagic flux occurs, p62, as substrate of autophagy itself, is 
degraded (29). Thus, increased LC3-II and decreased SQSTM1 levels are indicative of an 
appropriate autophagic activity whereas increased SQSTM1 levels, reveal defective autophagy (29). 
Recently, genes involved in autophagosomal/lysosomal biogenesis and lysosomal 
functionality, belonging to the Coordinated Lysosomal Expression and Regulation (CLEAR) 
network, have been described as crucial for a proper cell clearance through autophagic process (30) 
during catabolic conditions. In particular, the expression of the UVRAG (UV Radiation Resistance 
Associated) gene plays a pivotal role in the first phase of the process, which consists in the APs 
biogenesis and formation (31, 32). To ensure a proper degradation of unwanted material and thus 
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cell clearance, the APs must fuse to the lysosomes that contain several active hydrolases, such as β-
glucosidase, β-glucuronidaseand cathepsins (30). The fusion process depends on the intracellular 
positioning of lysosomes in that, only the lysosomes that are transported along microtubules in the 
perinuclear area, thanks to kinesins (such as KIF2A and KIF1B-β and the monomeric GTPase 
ARL8B), are able to fuse with APs (33). Moreover, Vps11 and Vps18 (Vacuolar Protein Sorting 11 
and 18) proteins products are also involved in vesicular trafficking to allow the encounter between 
APs and lysosomes, resulting in their fusion (34). Eventually, the formation of autolysosomes 
(ALs), whose content is degraded by lysosomal enzymes and recycled, leads to preserve cellular 
homeostasis. 
In this paper, submitted on Clinical Immunology, we indicate that in cells from A-T patients, 
the APs maturation is active, while the fusion between APs and lysosomes is inappropriate, thus 
implying abnormalities in the cell-clearance process. We also documented a positive effect of 
Betamethasone on molecules implicated in autophagosome degradation. 
  
66 
 
67 
 
68 
 
69 
 
70 
 
71 
 
72 
 
73 
 
74 
 
75 
 
  
76 
 
 
 
 
CHAPTER IV 
 
 
 
 
“Immunodeficiencies and Autoimmunity” 
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Even though Immunodeficiencies and autoimmunity may be considered two opposite conditions, 
deriving from different alterations of the immune system, several evidences suggested that PIDs are 
often associated with different autoimmune manifestations (95).  
            Autoimmunity in PIDs may be caused by different mechanisms, including defects of 
tolerance to self-antigens and persistent stimulation as a result of the inability to eradicate antigens.  
            This general immune dysregulation leads to compensatory and exaggerated chronic 
inflammatory responses that lead to tissue damage and autoimmunity.  
             Each PID may be characterized by distinct, peculiar autoimmune manifestations (96).  
 
             In the review published on Frontiers in Pediatrics, the main autoimmune manifestations 
and the pathogenetic mechanism underlying autoimmunity in a specific PID has are summarized.  
 
             
 
 
 
 
 
 
 
 
 
 
  
78 
 
79 
 
80 
 
81 
 
82 
 
83 
 
84 
 
85 
 
86 
 
 
  
87 
 
 
 
 
Chapter V 
 
 
 
 
Conclusive Remarks 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
88 
 
 
The immune system is a complex integrated network of chemical and cellular mediators that 
develops during evolution to defend the body from any form of chemical, traumatic or infective 
insult to their integrity.  
A proper immune response relies on the innate immunity, that is responsible for a first line of 
defense against aggression and the aspecific recognition of a limited repertoire of antigens, and, 
later, on the adaptative immunity which includes chemical and cellular mediators responsible for a 
more powerful and specific defensive response from any form of antigen. Alterations of any part of 
the immune response results in failure of host defense and, in particular, of immunodeficiency, 
autoimmunity and cancer predisposition.  
Primary immunodeficiency disorders (PIDs) are rare inherited disorders characterized by 
poor or absent function in one or more components of the immune system, that result in chronic, 
recurrent and life-threatening infections if not promptly diagnosed and treated (2). Traditionally, 
PIDs are classified according to the component of the immune system that is primarily disrupted: 
innate or adaptive immunity. In the last 20 years, thanks to the progress in molecular technologies, a 
remarkable improvement of the knowledge in the field of PIDs, concerning both their pathogenic 
mechanisms and clinical features, has been observed. Nowadays, about 300 forms of well-
characterized PIDs have been identified underlying complex phenotypes which encompass a wide 
spectrum of clinical features ranging from recurrent bacterial infections to other unusual 
manifestations, such as autoimmune disorders, cancer susceptibility, allergy and auto inflammation 
(8, 142). However, a recent study reported that PIDs are under diagnosed and, therefore, they are 
presumably more common than previously estimated. Thus far, the diagnosis of a specific PID has 
been based on the demonstration of a functional immune defect and on the subsequent identification 
of candidate genes, which are selectively involved in the biochemical pathway implicated in that 
specific functional alteration. 
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In this thesis, during the three years of my PhD program, I have contributed to elucidate 
“Novel insights in the pathogenesis of congenital immunodeficiencies”, through the clinical, 
cellular, functional and molecular study of some Immunological disorders. In particular, my 
research work has been focused on the positive effect of oral betamethasone administration on the 
lymphocytes functionality in patients affected of Ataxia-Telangiectasia, and the identification of the 
molecular checkpoint responsible for the partial functional rescue in lymphocytes of the patients 
affected with this disease. 
A further project described in this thesis concerns the evaluation of the pathogenic 
mechanisms, including the evaluation of cellular response to DNA injury, in patients with increased 
IgM levels, impaired B-cell homeostasis and high incidence of lymphoproliferation. NGS 
technologies revealed in two of them mutations in the PIK3R1 and ITPKB genes, implicated in T- 
and B-cell development and survival. This study highlights the possible role of polyclonal hyper 
IgM as biomarker of immune dysregulation and cancer susceptibility. 
 
Overall, the results obtained during my PhD course could be useful both in the clinical 
practice and in the basic research of immunological diseases. 
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